What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

By enacting the above suggestions, Bluebird Bio can show that it is confident in its product, that it will only get paid if the product works, that it will adjust costs if there is a need for future treatments and that it won’t be opportunistic in taking annual price hikes.

Read the full post on Forbes - Healthcare